{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n Indoleamine 2,3‐dioxygenase 2 (IDO2) is a tryptophan‐degrading enzyme that, although homologous to IDO1, exhibits a distinct tissue distribution, biochemical profile, and immunomodulatory function. Like its well‐studied counterpart, IDO2 can catalyze the conversion of tryptophan to kynurenine (1,2,3,9); however, its expression appears more restricted—in antigen‐presenting cells and select tissues such as the liver, kidney, and reproductive tract—and its enzymatic activity is differentially inhibited, with compounds like D‑1‑methyltryptophan displaying selectivity toward IDO2 (1,2,3,9). Moreover, emerging data suggest that IDO2 may not primarily regulate tryptophan levels per se but instead trigger unique downstream signaling events, including phosphorylation of eukaryotic initiation factor 2α (eIF2α) and the mobilization of inhibitory transcription isoforms (for example, LIP from NF‑IL6), thereby modulating immune responses independently of simple amino acid catabolism (1,2,3)."}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n In immune regulation, studies employing genetic deletion of IDO2 in mice have demonstrated that although baseline lymphocyte populations are unaffected, defects emerge upon immune stimulation, with aberrant T regulatory cell generation and altered cytokine responses that influence inflammatory outcomes (4,5,10). In autoimmune models—such as those of rheumatoid arthritis—IDO2 has been implicated as a critical mediator of autoreactive B cell responses, suggesting that its activity is nonredundant with IDO1 in driving pathogenic autoantibody production (10). In addition, in the setting of cancer, the differential targeting of IDO2 (for example, in pancreatic ductal adenocarcinoma) raises the possibility that selective inhibition of this enzyme may enhance antitumor immunity when used in combination with other immunotherapeutics (7)."}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n Finally, analysis of IDO2 expression patterns via immunohistochemistry further supports a specialized role for this enzyme in distinct cellular compartments and under inflammatory conditions (8). Collectively, these findings position IDO2 not merely as a redundant enzyme in tryptophan catabolism but as a unique immunomodulatory mediator whose differential regulation and signaling properties offer promising avenues for therapeutic targeting in cancer, autoimmunity, and other inflammation‐related diseases (1,2,3,4,5,7,8,9,10).\n "}]}, {"type": "t", "text": "\n \n "}, {"type": "p", "children": [{"type": "t", "text": "\n "}, {"type": "b", "children": [{"type": "t", "text": "Citations:"}]}, {"type": "t", "text": "<br>\n (1)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ",&nbsp;\n (2)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": ",&nbsp;\n (3)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "3"}]}, {"type": "t", "text": ",&nbsp;\n (4)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "4"}]}, {"type": "t", "text": ",&nbsp;\n (5)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "5"}]}, {"type": "t", "text": ",&nbsp;\n (7)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "6"}]}, {"type": "t", "text": ",&nbsp;\n (8)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "7"}]}, {"type": "t", "text": ",&nbsp;\n (9)"}, {"type": "fg", "children": [{"type": "fg_f", "ref": "8"}]}, {"type": "t", "text": ",&nbsp;\n (10)."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "9"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Richard Metz, James B Duhadaway, Uma Kamasani, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Res (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/0008-5472.CAN-07-1872"}], "href": "https://doi.org/10.1158/0008-5472.CAN-07-1872"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17671174"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17671174"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Helen J Ball, Angeles Sanchez-Perez, Silvia Weiser, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Gene (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.gene.2007.04.010"}], "href": "https://doi.org/10.1016/j.gene.2007.04.010"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17499941"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17499941"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Helen J Ball, Hajime J Yuasa, Christopher J D Austin, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Biochem Cell Biol (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.biocel.2008.01.005"}], "href": "https://doi.org/10.1016/j.biocel.2008.01.005"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18282734"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18282734"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Richard Metz, Courtney Smith, James B DuHadaway, et al. "}, {"type": "b", "children": [{"type": "t", "text": "IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int Immunol (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/intimm/dxt073"}], "href": "https://doi.org/10.1093/intimm/dxt073"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24402311"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24402311"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Stefan Lob, Alfred Konigsrainer, Richard Schafer, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Blood (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1182/blood-2007-10-116111"}], "href": "https://doi.org/10.1182/blood-2007-10-116111"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18045970"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18045970"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Agnieszka K Witkiewicz, Christina L Costantino, Richard Metz, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Am Coll Surg (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.jamcollsurg.2008.12.018"}], "href": "https://doi.org/10.1016/j.jamcollsurg.2008.12.018"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19476837"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19476837"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Masakazu Fukunaga, Yasuko Yamamoto, Misaki Kawasoe, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Histochem Cytochem (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1369/0022155412458926"}], "href": "https://doi.org/10.1369/0022155412458926"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22895526"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22895526"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Georgios Pantouris, Martynas Serys, Hajime J Yuasa, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Amino Acids (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s00726-014-1766-3"}], "href": "https://doi.org/10.1007/s00726-014-1766-3"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24875753"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24875753"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Lauren M F Merlo, Elizabeth Pigott, James B DuHadaway, et al. "}, {"type": "b", "children": [{"type": "t", "text": "IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Immunol (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.4049/jimmunol.1303012"}], "href": "https://doi.org/10.4049/jimmunol.1303012"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24489090"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24489090"}]}]}]}